Small Cell Lung Cancer (SCLC) is a specific subtype of lung cancer presenting as highly metastatic disease with extremely poor prognosis. Despite responding initially well to chemo- or radiotherapy, SCLC almost invariably relapses and develops resistance to chemotherapy. This is suspected to be related to tumor cell subpopulations with different characteristics resembling stem cells. Epithelial-Mesenchymal Transition (EMT) is known to play a key role in metastatic processes and in developing drug resistance. This is also true for NSCLC, but there is very little information on EMT processes in SCLC so far. SCLC, in contrast to NSCLC cell lines, grow mainly in floating cell clusters and a minor part as adherent cells. We compared these morpho...
Despite molecular and clinical heterogeneity, small cell lung cancer (SCLC) is treated as a single e...
Small cell lung cancer (SCLC) is an aggressive malignancy that includes subtypes defined by differen...
International audienceDespite the high response rates resulting from chemotherapy, the majority of s...
Small Cell Lung Cancer (SCLC) is a specific subtype of lung cancer presenting as highly metastatic d...
Non-Small Cell Lung Cancer (NSCLC) is a highly heterogeneous disease characterised by its aggressive...
Despite major advances, non-small cell lung cancer (NSCLC) remains the major cause of cancer-related...
Background Small cell lung cancer (SCLC) has a poor prognosis, and even with localized (limited) dis...
Small cell lung cancer (SCLC) is a high-grade neuroendocrine malignancy with an aggressive behavior ...
Despite the fact that the majority of cancer patients succumb to metastatic disease, most aspects of...
Tumors are often comprised of a multitude of cell types, a phenomenon called cellular heterogeneity,...
Cell lines are essential tools to standardize and compare experimental findings in basic and transla...
Small cell lung cancer (SCLC) is one of the most aggressive types of cancers. Despite being initiall...
The natural history of small cell lung cancer (SCLC) includes rapid evolution from chemosensitivity ...
Small cell lung cancer (SCLC; accounting for approximately 13%–15% of all lung cancers) is an except...
Small cell lung cancer (SCLC) is a neuroendocrine lung cancer characterized by fast growth, early di...
Despite molecular and clinical heterogeneity, small cell lung cancer (SCLC) is treated as a single e...
Small cell lung cancer (SCLC) is an aggressive malignancy that includes subtypes defined by differen...
International audienceDespite the high response rates resulting from chemotherapy, the majority of s...
Small Cell Lung Cancer (SCLC) is a specific subtype of lung cancer presenting as highly metastatic d...
Non-Small Cell Lung Cancer (NSCLC) is a highly heterogeneous disease characterised by its aggressive...
Despite major advances, non-small cell lung cancer (NSCLC) remains the major cause of cancer-related...
Background Small cell lung cancer (SCLC) has a poor prognosis, and even with localized (limited) dis...
Small cell lung cancer (SCLC) is a high-grade neuroendocrine malignancy with an aggressive behavior ...
Despite the fact that the majority of cancer patients succumb to metastatic disease, most aspects of...
Tumors are often comprised of a multitude of cell types, a phenomenon called cellular heterogeneity,...
Cell lines are essential tools to standardize and compare experimental findings in basic and transla...
Small cell lung cancer (SCLC) is one of the most aggressive types of cancers. Despite being initiall...
The natural history of small cell lung cancer (SCLC) includes rapid evolution from chemosensitivity ...
Small cell lung cancer (SCLC; accounting for approximately 13%–15% of all lung cancers) is an except...
Small cell lung cancer (SCLC) is a neuroendocrine lung cancer characterized by fast growth, early di...
Despite molecular and clinical heterogeneity, small cell lung cancer (SCLC) is treated as a single e...
Small cell lung cancer (SCLC) is an aggressive malignancy that includes subtypes defined by differen...
International audienceDespite the high response rates resulting from chemotherapy, the majority of s...